吡利黴素
吡利黴素是一種林可醯胺類抗生素,專為泌乳期乳牛的乳房內灌注而配製。主要用於治療由敏感革蘭氏陽性菌引起的臨床和亞臨床乳腺炎。 * **主要病原體**:對葡萄球菌屬(包括金黃色葡萄球菌、表皮葡萄球菌等)、鏈球菌屬(無乳鏈球菌、停乳鏈球菌等)及糞腸球菌具有高度活性。 * **臨床要點**:與某些舊型乳腺炎配方不同,吡利黴素具有極佳的組織穿透力,能深入乳房實質組織治療深層感染,而不僅僅停留在乳汁中。 > **注意**:MIC ≤ 2 mcg/mL 的細菌被視為具感受性,而 MIC ≥ 4 mcg/mL 則被視為具抗藥性。
作用機制: Pirlimycin shares its mechanism of action with other **lincosamide** antibiotics (such as clindamycin and lincomycin). * **Mechanism**: Binds reversibly to the **50S ribosomal subunit** of susceptible bacterial RNA. * **Pathway**: Inhibits peptidyl transferase → prevents peptide bond formation → **interferes with bacterial protein synthesis**. * **Activity**: Generally considered **bacteriostatic**, but can be bactericidal at high concentrations against highly susceptible organisms. It is a time-dependent antibiotic.
各物種劑量
- Clinical and subclinical mastitis · Infuse contents of one syringe into each affected quarter · Intramammary · q24h · Repeat after 24 hours. May be repeated daily for up to 8 consecutive days. · Use proper teat end preparation, sanitation, and intramammary infusion technique.
劑量為持牌獸醫專業人員的臨床參考。請務必對照最新藥品說明書及個別病患確認。
給藥途徑
禁忌症
- Known hypersensitivity to lincosamides
不良反應
- No adverse effects or udder irritation have been reported at labeled doses
藥物相互作用
- Erythromycin · Potential in vitro antagonism; may compete for the same ribosomal binding site
- Clindamycin · Potential in vitro antagonism; may compete for the same ribosomal binding site
監測
- Clinical efficacy (resolution of mastitis signs, somatic cell counts)
- Strict adherence to withdrawal periods
過量
No specific data is available regarding acute toxicity or overdosage. If an overdose occurs, monitor for signs of local irritation or systemic gastrointestinal upset, and observe extended withdrawal times.
VetSheet 藥物參考供持牌獸醫專業人員作臨床決策輔助之用,不能取代專業判斷或廠方最新藥品說明書。